Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 431 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 See How These Food Banks Are Putting Your Feed Thy Neighbor... February 9, 2021 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 9 Ways To Teach Kids To Be Confident (Without Teaching Them... October 24, 2019 Load more HOT NEWS Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’... Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia EMA Recommends Extension of Indications for Cemiplimab
